Diagnostic utility of (18)f-fluciclovine positron emission tomography (FACBC) in biochemically recurrent (BCR) prostate cancer (PCa) based on prior primary treatment modality for localized disease and the impact of FACBC findings on treatment selection.

Marina N. Sharifi,Petra Lovrec,Jens C. Eickhoff,Aria Kenarsary,David Frazier Jarrard,John M. Floberg,Steve Y. Cho,Christos Kyriakopoulos,Hamid Emamekhoo

Diagnostic utility of (18)f-fluciclovine positron emission tomography (FACBC) in biochemically recurrent (BCR) prostate cancer (PCa) based on prior primary treatment modality for localized disease and the impact of FACBC findings on treatment selection.

2021

Marina N. Sharifi
Petra Lovrec
Jens C. Eickhoff
Aria Kenarsary
David Frazier Jarrard
John M. Floberg
Steve Y. Cho
Christos Kyriakopoulos
Hamid Emamekhoo

34Background: Management of BCR PCa requires accurate assessment of location and extent of recurrent disease. FACBC has been shown to be a sensitive modality for detection and localization of recur...

Keywords:

Prostate cancer
Positron emission tomography
Localized disease
recurrent disease
prior primary treatment
Radiology
breakpoint cluster region
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations